Table 1.
Patient demographics
| Characteristic | Median (range) | No. | % |
| Number of patients treated | – | 29 | – |
| Age, years | 65 (41–80) | – | – |
| Disease stage | |||
| IIC | – | 1 | 3.4 |
| III | – | 21 | 72.4 |
| IV | – | 7 | 24.1 |
| Histology | |||
| Serous | 26 | 90 | |
| Non-serous | 3 | 10 | |
| Number of previous chemotherapy regimens | 4 (2–9) | – | – |
| Prior bevacizumab therapy | – | 21 | 72.4 |
| Prior PARP inhibitor therapy | – | 9 | 31.0 |
| RECIST V.1.1 tumor burden | |||
| Number of target lesions | 3 (1–5) | 29 | – |
| Size of longest diameter in largest target lesion (mm) | 32.8 (14.8–124.4) | 29 | – |
| RECIST V.1.1 total | 65.3 (15–198.2) | 29 | – |
| BRCA status | |||
| BRCA1 | – | 4 | 13.8 |
| BRCA2 | – | 1 | 3.4 |
| Negative | – | 23 | 79.3 |
| Unknown | – | 1 | 3.4 |